UY30616A1 - Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico - Google Patents
Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmicoInfo
- Publication number
- UY30616A1 UY30616A1 UY30616A UY30616A UY30616A1 UY 30616 A1 UY30616 A1 UY 30616A1 UY 30616 A UY30616 A UY 30616A UY 30616 A UY30616 A UY 30616A UY 30616 A1 UY30616 A1 UY 30616A1
- Authority
- UY
- Uruguay
- Prior art keywords
- growth factor
- therapeutic compositions
- epidermal growth
- therapy
- enhance
- Prior art date
Links
- 102000009024 Epidermal Growth Factor Human genes 0.000 title abstract 3
- 101800003838 Epidermal growth factor Proteins 0.000 title abstract 3
- 229940116977 epidermal growth factor Drugs 0.000 title abstract 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 102000014150 Interferons Human genes 0.000 abstract 3
- 108010050904 Interferons Proteins 0.000 abstract 3
- 229940047124 interferons Drugs 0.000 abstract 2
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion describe composiciones terapéuticas específicas, que aumentan la eficacia de la terapia con anticuerpos monoclonales (AcMs) contra el receptor del Factor de Crecimiento Epidérmico (EGFR, del inglés "epidermal growth factor receptor") e interferones (INFs) de tipo I (a(alfa)/B(Beta)).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20060190A CU23612A1 (es) | 2006-09-29 | 2006-09-29 | Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30616A1 true UY30616A1 (es) | 2008-05-02 |
Family
ID=40223744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY30616A UY30616A1 (es) | 2006-09-29 | 2007-09-28 | Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100047207A1 (es) |
| EP (1) | EP2070547B1 (es) |
| KR (1) | KR101482957B1 (es) |
| CN (2) | CN102940883A (es) |
| AR (1) | AR063011A1 (es) |
| AU (1) | AU2007302429B2 (es) |
| BR (1) | BRPI0717142A2 (es) |
| CA (1) | CA2664795C (es) |
| CL (1) | CL2007002797A1 (es) |
| CO (1) | CO6160338A2 (es) |
| CR (1) | CR10753A (es) |
| CU (1) | CU23612A1 (es) |
| MA (1) | MA30811B1 (es) |
| MX (1) | MX2009003159A (es) |
| PE (1) | PE20080674A1 (es) |
| TN (1) | TN2009000104A1 (es) |
| TR (1) | TR200902344T1 (es) |
| UY (1) | UY30616A1 (es) |
| WO (1) | WO2008037225A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI500630B (zh) * | 2008-06-20 | 2015-09-21 | Centro Inmunologia Molecular | 具有細胞生長抑制功效之表皮生長因子受體（ｅｇｆｒ）抑制劑類及彼等於腫瘤治療上之用途 |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| MY188446A (en) * | 2015-07-27 | 2021-12-09 | Innocimab Pte Ltd | Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| DE69324671D1 (de) * | 1992-02-10 | 1999-06-02 | Interferon Sciences Inc | Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute |
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| BR0209147A (pt) * | 2001-05-08 | 2004-06-08 | Merck Patent Gmbh | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais |
| US20060134064A1 (en) * | 2004-12-20 | 2006-06-22 | David Goldstein | Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor |
| US20110189178A1 (en) * | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
-
2006
- 2006-09-29 CU CU20060190A patent/CU23612A1/es unknown
-
2007
- 2007-09-26 AR ARP070104260A patent/AR063011A1/es unknown
- 2007-09-27 MX MX2009003159A patent/MX2009003159A/es active IP Right Grant
- 2007-09-27 CN CN2012104701143A patent/CN102940883A/zh active Pending
- 2007-09-27 KR KR1020097007699A patent/KR101482957B1/ko not_active Expired - Fee Related
- 2007-09-27 PE PE2007001310A patent/PE20080674A1/es not_active Application Discontinuation
- 2007-09-27 CL CL200702797A patent/CL2007002797A1/es unknown
- 2007-09-27 US US12/442,608 patent/US20100047207A1/en not_active Abandoned
- 2007-09-27 BR BRPI0717142-0A patent/BRPI0717142A2/pt not_active IP Right Cessation
- 2007-09-27 CN CN200780036290A patent/CN101678099A/zh active Pending
- 2007-09-27 CA CA2664795A patent/CA2664795C/en not_active Expired - Fee Related
- 2007-09-27 TR TR2009/02344T patent/TR200902344T1/xx unknown
- 2007-09-27 AU AU2007302429A patent/AU2007302429B2/en not_active Ceased
- 2007-09-27 WO PCT/CU2007/000017 patent/WO2008037225A1/es not_active Ceased
- 2007-09-27 EP EP07817381.2A patent/EP2070547B1/en not_active Not-in-force
- 2007-09-28 UY UY30616A patent/UY30616A1/es not_active Application Discontinuation
-
2009
- 2009-03-25 CO CO09030399A patent/CO6160338A2/es unknown
- 2009-03-27 TN TN2009000104A patent/TN2009000104A1/fr unknown
- 2009-04-23 MA MA31815A patent/MA30811B1/fr unknown
- 2009-04-29 CR CR10753A patent/CR10753A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR063011A1 (es) | 2008-12-23 |
| CA2664795C (en) | 2014-06-17 |
| BRPI0717142A2 (pt) | 2013-10-15 |
| PE20080674A1 (es) | 2008-07-23 |
| EP2070547B1 (en) | 2013-04-24 |
| CN101678099A (zh) | 2010-03-24 |
| KR20090058566A (ko) | 2009-06-09 |
| CO6160338A2 (es) | 2010-05-20 |
| EP2070547A1 (en) | 2009-06-17 |
| CL2007002797A1 (es) | 2008-04-18 |
| CA2664795A1 (en) | 2008-04-03 |
| AU2007302429B2 (en) | 2013-10-03 |
| TN2009000104A1 (en) | 2010-08-19 |
| CU23612A1 (es) | 2010-12-08 |
| CN102940883A (zh) | 2013-02-27 |
| EP2070547A4 (en) | 2011-11-02 |
| MX2009003159A (es) | 2009-04-06 |
| CR10753A (es) | 2009-10-15 |
| MA30811B1 (fr) | 2009-10-01 |
| TR200902344T1 (tr) | 2009-08-21 |
| WO2008037225A1 (es) | 2008-04-03 |
| KR101482957B1 (ko) | 2015-01-15 |
| AU2007302429A1 (en) | 2008-04-03 |
| US20100047207A1 (en) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022002622A2 (es) | Anticuerpos anti-cd73 y composiciones | |
| UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
| CL2008003788A1 (es) | Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20. | |
| ECSP11011450A (es) | ANTICUERPOS ANTI-TNF-a Y SUS USOS | |
| HN2011001210A (es) | Anticuerpos humanos de alta afinidad para el receptor il-4 humano | |
| AR112564A2 (es) | Anticuerpos humanizados contra el receptor del linfoma de burkitt (anti-cxcr5) | |
| CR10099A (es) | Inmunoglobulinas dirigidas contra nogo | |
| AR074563A1 (es) | Anticuerpos anti ligando 1 de muerte programada (anti-pd-l1) y su uso para mejorar la funcion de las celulas t | |
| UA111818C2 (uk) | Антитіло проти csf-1r | |
| GT200500298A (es) | Formulaciones de anticuerpos | |
| CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
| CR9253A (es) | Fijacion de la dosificacion de anticuerpos her | |
| AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| AR069981A1 (es) | Los "anticuerpo modificado geneticamente que reconocen cd138". | |
| CR20130016A (es) | ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
| BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| PA8846101A1 (es) | Anticuerpos del receptor ii anti-tgf-beta | |
| MX2018003410A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| EA200802247A1 (ru) | Схема дозирования кладрибина для лечения рассеянного склероза | |
| AR077867A1 (es) | Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona | |
| BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| GT200900031A (es) | Aplicacion por via transdermica de triazinas para combatir infecciones por coccidios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20170725 |